Pharmaceutical Drug Delivery Market by Route (Oral (Tablet), Pulmonary (Nebulizer), Injectable, Ocular (Liquid), Topical (Solid), Implantable (Active), Transmucosal), Application (Cancer, Diabetes), Patient Care Setting (Hospital) - Global Forecast to 2023

薬剤送達システムの世界市場予測(~2023年)

◆タイトル:Pharmaceutical Drug Delivery Market by Route (Oral (Tablet), Pulmonary (Nebulizer), Injectable, Ocular (Liquid), Topical (Solid), Implantable (Active), Transmucosal), Application (Cancer, Diabetes), Patient Care Setting (Hospital) - Global Forecast to 2023
◆商品コード:MD 3871
◆調査・発行会社:MarketsandMarkets
◆発行日:2019年3月5日
◆ページ数:290
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥610,200見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥718,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥880,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

薬剤送達システムの世界市場は、2018年の1兆2,444億米ドルから2023年には1兆6,947億米ドルに達し、この期間中6.4%の年平均成長率で成長すると予測されています。この市場の成長を促す要因として、慢性疾患数の増加、生物製剤市場の成長、そして技術の進歩と新たな商品展開が考えられます。一方で、針刺し事故のリスクと価格圧力の高まりは、市場成長の課題となることが予測されます。当調査レポートでは、薬剤送達システムの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、投与経路(経口、経肺、注射、経眼、局所、植え込み、経粘膜)分析、用途(がん、糖尿病)分析、患者管理の環境(病院)分析、薬剤送達システムの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

“Rising prevalence for chronic diseases and growth in the biologics market are expected to drive the overall growth of the pharmaceutical drug delivery market.”The global pharmaceutical drug delivery market is projected to reach USD 1,694.7 billion by 2023 from USD 1,244.4 billion in 2018, at a CAGR of 6.4% during the forecast period. Growth in this market is mainly driven by the rising prevalence of chronic diseases, growth in the biologics market, and technological advancements and new product launches. On the other hand, the risk of needlestick injuries and the increasing pricing pressure are expected to challenge market growth in the coming years.

“The home care settings segment is expected to grow at the highest CAGR during the forecast period.”
Based on facility of use, the pharmaceutical drug delivery market is segmented hospitals, ambulatory surgical centers (ASCs)/clinics, diagnostic centers, home care settings, and other facilities of use. The home care settings segment is expected to grow at a higher CAGR during the forecast period. This can majorly be attributed to increasing use of various drug delivery devices such as injectables, nebulizers, and inhalers in home care settings.

“The conventional injection devices segment accounted for the largest share of the injectable drug delivery market in 2018.”
Based on type, the injectable drug delivery technology is segmented into conventional injection devices, self-injection devices, and other devices. In 2018, conventional injection devices accounted for the largest share of the injectable drug delivery technology market. The large share of this segment can primarily be attributed to factors such as the low cost of devices and manufacturing, large molecular size of biologics administered through injectables, and the widespread popularity of conventional devices.

“North America to dominate the market during the forecast period.”
In 2018, North America accounted for the largest share of the pharmaceutical drug delivery market. The large share of the North American market is due to factors such as the rising prevalence of chronic diseases such as cancer, respiratory allergies, and diabetes; growth in biologics in the pharmaceuticals market; and the presence of a large number of prominent players in this region.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 (55%), Tier 2 (25%), and Tier 3 (20%)
• By Designation: C-level (43%), D-level (32%), and Others (25%)
• By Region: North America (38%), Europe (23%), Asia (29%), and RoW (10%)

List of Companies Profiled in the Report
• Johnson & Johnson, Inc. (US)
• F. Hoffman-La Roche (Switzerland)
• Merck & Co., Inc. (US)
• Bayer AG (Germany)
• Pfizer, Inc. (US)
• Novartis AG (Switzerland)
• 3M Company (US)
• Becton, Dickinson and Company (US)
• GlaxoSmithKline plc, (UK)
• Sanofi (France)
• Antares Pharma, Inc. (US).

Research Coverage:
This report provides a detailed picture of the global pharmaceutical drug delivery market. It aims at estimating the size and future growth potential of the market across different segments, such as route of administration, application, facility of use, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmaceutical drug delivery market and its subsegments. This report will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, challenges, and opportunities.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 28
1.1 OBJECTIVES OF THE STUDY 28
1.2 MARKET DEFINITION 28
1.3 MARKET SCOPE 29
1.3.1 MARKETS COVERED 29
1.3.2 YEARS CONSIDERED FOR THE STUDY 29
1.4 CURRENCY 30
1.5 LIMITATIONS 30
1.6 STAKEHOLDERS 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
2.1.1 SECONDARY DATA 33
2.1.1.1 Key data from secondary sources 33
2.1.2 PRIMARY DATA 34
2.1.2.1 Key data from primary sources 35
2.1.2.2 Key industry insights 36
2.2 MARKET SIZE ESTIMATION 36
2.2.1 MARKET DATA VALIDATION AND TRIANGULATION 38
2.3 ASSUMPTIONS FOR THE STUDY 39
3 EXECUTIVE SUMMARY 40
4 PREMIUM INSIGHTS 44
4.1 DRUG DELIVERY TECHNOLOGY: MARKET OVERVIEW 44
4.2 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION,
2018 VS. 2023 (USD BILLION) 45
4.3 DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE,
2018–2023 (USD BILLION) 45
4.4 DRUG DELIVERY TECHNOLOGY MARKET SHARE, BY APPLICATION AND REGION, 2018 46
4.5 DRUG DELIVERY TECHNOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS 48
5.3 DRIVERS 49
5.3.1 RISING PREVALENCE OF CHRONIC DISEASES 49
5.3.2 GROWTH IN THE BIOLOGICS MARKET 50
5.3.3 TECHNOLOGICAL ADVANCEMENTS AND NEW PRODUCT LAUNCHES 50
5.4 RESTRAINTS 51
5.4.1 RISK OF NEEDLESTICK INJURIES 51
5.5 OPPORTUNITIES 51
5.5.1 SELF-ADMINISTRATION AND HOME CARE 51
5.5.2 RISING DEMAND FOR BIOSIMILARS 52
5.6 CHALLENGES 52
5.6.1 PRICING PRESSURE 52
6 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION 53
6.1 INTRODUCTION 54
6.2 ORAL DRUG DELIVERY 55
6.2.1 SOLID ORAL DRUGS 57
6.2.1.1 Tablets 58
6.2.1.1.1 Development of mini-tablets is a key trend in this market segment. 58
6.2.1.2 Capsules 58
6.2.1.2.1 Easy absorption of drugs and decreased irritation in the GI tract are driving the use of capsules 58
6.2.1.3 Powders 59
6.2.1.3.1 Powders are taken by patients who are unable to swallow oral dosage forms 59
6.2.1.4 Pills 60
6.2.1.4.1 Rising incidence of target ailments will propel the growth of the pills market 60
6.2.2 LIQUID ORAL DRUGS 61
6.2.2.1 Syrups 62
6.2.2.1.1 Liquid syrups can be easily administered to patients with swallowing difficulties 62
6.2.2.2 Solutions 63
6.2.2.2.1 Solutions are generally preferred by geriatric and pediatric patients 63
6.2.3 SEMI-SOLID ORAL DRUGS 64
6.2.3.1 Gels 65
6.2.3.1.1 Gels are used for controlled drug release 65
6.2.3.2 Emulsions 65
6.2.3.2.1 Microemulsions offer protection against oxidation and enzymatic hydrolysis 65
6.2.3.3 Elixirs 66
6.2.3.3.1 Elixirs are hydraulic in nature and contain sweet and flavored substances 66
6.3 INJECTABLE DRUG DELIVERY 67
6.3.1 CONVENTIONAL INJECTION DEVICES 68
6.3.1.1 By material 69
6.3.1.1.1 Glass 70
6.3.1.1.1.1 Glass syringes are considered to be one of the most durable and safe materials to store biologic drugs 70
6.3.1.1.2 Plastic 71
6.3.1.1.2.1 Plastic syringes are reasonably priced as compared to their glass counterparts 71
6.3.1.2 By product 72
6.3.1.2.1 Fillable syringes 72
6.3.1.2.1.1 Ease of use and variable dosing formulations of fillable syringes are the major factors driving market growth 72
6.3.1.2.2 Prefilled syringes 73
6.3.1.2.2.1 Prefilled syringes offer improved dose accuracy and increased patient convenience and safety 73
6.3.1.3 By usability 74
6.3.1.3.1 Reusable syringes 74
6.3.1.3.1.1 Reusable syringes are easy to dismantle and clean 74
6.3.1.3.2 Disposable syringes 75
6.3.1.3.2.1 Disposable syringes are widely used in medical practices due to their low cost and convenience 75
6.3.2 SELF-INJECTION DEVICES 76
6.3.2.1 Needle-free injectors 77
6.3.2.1.1 Needle-free injectors enable fast drug delivery and show better reproducibility as compared to invasive drug delivery systems 77
6.3.2.2 Autoinjectors 78
6.3.2.2.1 Autoinjectors provide improved patient satisfaction as compared to manual injections 78
6.3.2.3 Pen injectors 78
6.3.2.3.1 Pen injectors are generally used when medications have to be administered more than once a week 78
6.3.2.4 Wearable injectors 79
6.3.2.4.1 Increasing adoption of home infusion therapy and rising focus on cost-curtailment in healthcare are supporting market growth 79
6.3.3 OTHER INJECTOR DEVICES 80
6.4 TOPICAL DRUG DELIVERY 80
6.4.1 LIQUID FORMULATIONS 82
6.4.1.1 Solutions 83
6.4.1.1.1 Solutions accounted for a larger share of the topical drug delivery technology market for liquid formulations in 2018 83
6.4.1.2 Suspensions 83
6.4.1.2.1 Factors such as higher rate of bioavailability and controlled onset of action to support the growth of the topical suspensions market in the coming years 83
6.4.2 SEMI-SOLID FORMULATIONS 84
6.4.2.1 Creams 85
6.4.2.1.1 Creams are either water-in-oil or oil-in-water emulsions 85

6.4.2.2 Gels 86
6.4.2.2.1 Factors such as faster drug release and greater patient acceptability to drive the market for topical gels 86
6.4.2.3 Ointments 86
6.4.2.3.1 Ointments are widely used in analgesic indications 86
6.4.2.4 Pastes 87
6.4.2.4.1 Topical pastes are widely used for the treatment and prevention of skin irritation 87
6.4.2.5 Lotions 88
6.4.2.5.1 Easy administration of lotions to drive their demand among end users 88
6.4.3 SOLID FORMULATIONS 88
6.4.3.1 Suppositories 89
6.4.3.1.1 Suppositories require a suitable base that ensures the compatibility and stability of the drug 89
6.4.3.2 Powders 90
6.4.3.2.1 Powders have a very fine particle size that covers a large surface area per unit weight 90
6.4.4 TRANSDERMAL PRODUCTS 90
6.4.4.1 Transdermal patches 91
6.4.4.1.1 Transdermal patches prevent the premature metabolization of the drug through the liver 91
6.4.4.2 Transdermal gels 92
6.4.4.2.1 Transdermal gels help in the faster release of drugs on the target site 92
6.5 OCULAR DRUG DELIVERY 93
6.5.1 LIQUID FORMULATIONS 95
6.5.1.1 Eye drops 96
6.5.1.1.1 Rising prevalence of cataracts and other eye diseases is driving market growth 96
6.5.1.2 Liquid sprays 97
6.5.1.2.1 Liquid sprays have helped in overcoming drawbacks associated with traditional eye drops 97
6.5.2 SEMI-SOLID FORMULATIONS 97
6.5.2.1 Gels 98
6.5.2.1.1 High viscosity of drugs, prolonged drug release, and ease of drug administration are factors contributing to market growth 98
6.5.2.2 Eye ointments 99
6.5.2.2.1 Eye ointments are safe to use, and help in improving ocular contact time with the drug 99
6.5.3 OCULAR DEVICES 99
6.5.3.1 Drug-coated contact lenses 100
6.5.3.1.1 Better eyesight offered by lenses & high compliance to drive the market for drug-coated contact lenses 100

6.5.3.2 Ocular inserts 101
6.5.3.2.1 Ocular inserts help in the sustained release of drugs in the eye 101
6.6 PULMONARY DRUG DELIVERY 102
6.6.1 METERED-DOSE INHALERS 103
6.6.1.1 These inhalers overcome the problem of poor coordination between inhaler actuation and patient breath 103
6.6.2 DRY POWDER INHALERS 104
6.6.2.1 DPI drug formulations are chemically more stable than their counterparts are 104
6.6.3 NEBULIZERS 105
6.6.3.1 Jet nebulizers 106
6.6.3.1.1 Jet nebulizers account for the largest share of the nebulizers market 106
6.6.3.2 Ultrasonic nebulizers 107
6.6.3.2.1 Ultrasonic nebulizers are easy to use and comfortable to handle 107
6.6.3.3 Soft mist nebulizers 108
6.6.3.3.1 Soft Mist nebulizers are preferred for the treatment of severe COPD 108
6.7 NASAL DRUG DELIVERY 108
6.7.1 NASAL DROPS 110
6.7.1.1 Nasal drops are considered more efficient than nasal sprays 110
6.7.2 NASAL SPRAYS 110
6.7.2.1 Nasal sprays help in relieving nasal congestion, runny nose, itchy nose, and sneezing 110
6.7.3 NASAL POWDERS 111
6.7.3.1 Absence of preservatives & superior stability of formulations are some of the advantages associated with nasal powders 111
6.7.4 NASAL GELS 112
6.7.4.1 Nasal gels provide long-lasting relief from dry nasal passages and also reduce irritation caused by using soothing excipients 112
6.8 TRANSMUCOSAL DRUG DELIVERY 112
6.8.1 ORAL FORMULATIONS 114
6.8.1.1 Buccal drug delivery 115
6.8.1.1.1 Buccal drug delivery system is suitable for local and systematic therapies 115
6.8.1.2 Sublingual drug delivery 116
6.8.1.2.1 The rate of drug absorption through the sublingual route is 3–10 times higher than the oral route 116
6.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES 117
6.8.2.1 Rectal transmucosal drug delivery 118
6.8.2.1.1 The rectal route of drug delivery rapidly absorbs drugs that are aqueous in nature 118

6.8.2.2 Vaginal transmucosal drug delivery 118
6.8.2.2.1 The permeability of the drug is high through the vaginal route of administration 118
6.9 IMPLANTABLE DRUG DELIVERY 119
6.9.1 ACTIVE IMPLANTABLE DRUG DELIVERY 121
6.9.1.1 Active implantable devices are used for diagnostic monitoring, body fluids transportation, and ionized radiation 121
6.9.2 PASSIVE IMPLANTABLE DRUG DELIVERY 122
6.9.2.1 Passive implants primarily include joint replacements, heart valves, aneurysm clips, coronary stents, and breast implants 122
7 DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE 123
7.1 INTRODUCTION 124
7.2 HOSPITALS 125
7.2.1 HOSPITALS WILL CONTINUE TO DOMINATE THE DRUG DELIVERY TECHNOLOGY MARKET DURING THE FORECAST PERIOD 125
7.3 AMBULATORY SURGERY CENTERS/CLINICS 125
7.3.1 INCREASING PREFERENCE FOR ASCS HAS RESULTED IN A SIGNIFICANT RISE IN DEMAND FOR DRUG DELIVERY TECHNOLOGIES 125
7.4 HOME CARE SETTINGS 126
7.4.1 HOME CARE SETTINGS TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 126
7.5 DIAGNOSTIC CENTERS 127
7.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH 127
7.6 OTHER FACILITIES OF USE 128
8 DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION 129
8.1 INTRODUCTION 130
8.2 INFECTIOUS DISEASES 131
8.2.1 HIGH BURDEN OF INFECTIOUS DISEASES ACROSS THE GLOBE TO DRIVE MARKET GROWTH 131
8.3 CANCER 132
8.3.1 CANCER FORMS A KEY THERAPEUTIC APPLICATION SEGMENT FOR DRUG DELIVERY TECHNOLOGIES 132
8.4 CARDIOVASCULAR DISEASES 133
8.4.1 INCREASING PREVALENCE OF CVDS IS DRIVING THE GROWTH OF THE DRUG DELIVERY TECHNOLOGY MARKET 133
8.5 DIABETES 134
8.5.1 EMERGENCE OF NEW TECHNOLOGIES IS SUPPORTING MARKET GROWTH 134
8.6 RESPIRATORY DISEASES 135
8.6.1 HIGH PREVALENCE OF ASTHMA & COPD TO DRIVE THE ADOPTION OF DRUG DELIVERY TECHNOLOGIES 135
8.7 CENTRAL NERVOUS SYSTEM DISORDERS 136
8.7.1 ORAL AND INJECTABLE DRUG DELIVERY SYSTEMS ARE WIDELY USED IN THE TREATMENT OF CNS DISORDERS 136
8.8 AUTOIMMUNE DISEASES 137
8.8.1 AUTOIMMUNE DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD 137
8.9 OTHER APPLICATIONS 138
8.9.1 OPHTHALMIC DISORDERS 138
8.9.2 ENDOCRINE DISORDERS 138
9 DRUG DELIVERY TECHNOLOGY MARKET, BY REGION 139
9.1 INTRODUCTION 140
9.2 NORTH AMERICA 140
9.2.1 US 152
9.2.1.1 Rising prevalence of chronic diseases and strong presence of key market players – Major factors driving market growth in the US 152
9.2.2 CANADA 153
9.2.2.1 Government support for research and the rising prevalence of chronic diseases are the major factors driving market growth in Canada 153
9.3 EUROPE 155
9.3.1 GERMANY 166
9.3.1.1 Growing focus of pharmaceutical companies on the development of various drug delivery products is expected to drive market growth in Germany 166
9.3.2 FRANCE 168
9.3.2.1 High insurance coverage coupled with the increasing prevalence of chronic diseases to drive market growth in France 168
9.3.3 UK 169
9.3.3.1 Increasing incidence and prevalence of chronic and infectious diseases to drive the demand for drug delivery technologies in the UK 169
9.3.4 REST OF EUROPE 171
9.4 ASIA PACIFIC 172
9.4.1 JAPAN 184
9.4.1.1 Favorable government initiatives and increasing geriatric population will drive market growth in Japan 184
9.4.2 CHINA 186
9.4.2.1 China had the largest diabetic population in the world in 2017 186
9.4.3 INDIA 187
9.4.3.1 Favorable initiatives and high disease incidence will drive market growth in India 187
9.4.4 REST OF ASIA PACIFIC 189
9.5 REST OF THE WORLD 190
10 COMPETITIVE LANDSCAPE 202
10.1 OVERVIEW 202
10.2 MARKET PLAYER RANKING, 2017 203
10.3 COMPETITIVE SCENARIO 204
10.4 COMPETITIVE LEADERSHIP MAPPING (2017) 206
10.4.1 VENDOR INCLUSION CRITERIA 206
10.4.2 VISIONARY LEADERS 206
10.4.3 INNOVATORS 206
10.4.4 DYNAMIC DIFFERENTIATORS 206
10.4.5 EMERGING COMPANIES 206
10.5 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2017) 208
10.5.1 PROGRESSIVE COMPANIES 208
10.5.2 STARTING BLOCKS 208
10.5.3 RESPONSIVE COMPANIES 208
10.5.4 DYNAMIC COMPANIES 208
11 COMPANY PROFILE 210
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1 JOHNSON & JOHNSON SERVICES, INC. 210
11.2 NOVARTIS AG 221
11.3 F. HOFFMANN-LA ROCHE LTD. 231
11.4 PFIZER, INC. 236
11.5 BAYER AG 249
11.6 ANTARES PHARMA, INC. 254
11.7 BECTON, DICKINSON AND COMPANY 256
11.8 GLAXOSMITHKLINE PLC 260
11.9 3M 267
11.10 MERCK & CO., INC. 269
11.11 SANOFI 276
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
12 APPENDIX 282
12.1 DISCUSSION GUIDE 282
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 286
12.3 AVAILABLE CUSTOMIZATIONS 288
12.4 RELATED REPORTS 288
12.5 AUTHOR DETAILS 289

LIST OF TABLES

TABLE 1 INDICATIVE LIST OF BIOLOGICS APPROVED BY THE FDA (2017) 50
TABLE 2 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION,
2016–2023 (USD BILLION) 55
TABLE 3 ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY,
2016–2023 (USD BILLION) 56
TABLE 4 ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM,
2016–2023 (USD BILLION) 56
TABLE 5 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS,
BY DOSAGE FORM, 2016–2023 (USD BILLION) 57
TABLE 6 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY REGION, 2016–2023 (USD BILLION) 57
TABLE 7 CAPSULES MARKET, BY REGION, 2016–2023 (USD BILLION) 59
TABLE 8 POWDERS MARKET, BY REGION, 2016–2023 (USD BILLION) 60
TABLE 9 PILLS MARKET, BY REGION, 2016–2023 (USD BILLION) 60
TABLE 10 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2016–2023 (USD BILLION) 61
TABLE 11 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY REGION, 2016–2023 (USD BILLION) 61
TABLE 12 ORAL SYRUPS MARKET, BY REGION, 2016–2023 (USD BILLION) 62
TABLE 13 ORAL SOLUTIONS MARKET, BY REGION, 2016–2023 (USD BILLION) 63
TABLE 14 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS,
BY DOSAGE FORM, 2016–2023 (USD BILLION) 64
TABLE 15 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS,
BY REGION, 2014–2021 (USD BILLION) 64
TABLE 16 ORAL GELS MARKET, BY REGION, 2016–2023 (USD BILLION) 65
TABLE 17 ORAL EMULSIONS MARKET, BY REGION, 2016–2023 (USD BILLION) 66
TABLE 18 ELIXIRS MARKET, BY REGION, 2016–2023 (USD MILLION) 66
TABLE 19 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY,
2016–2023 (USD BILLION) 67
TABLE 20 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD BILLION) 68
TABLE 21 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD BILLION) 68
TABLE 22 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY REGION, 2016–2023 (USD BILLION) 69
TABLE 23 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016–2023 (USD BILLION) 69
TABLE 24 GLASS SYRINGES MARKET, BY REGION, 2016–2023 (USD BILLION) 70
TABLE 25 PLASTIC SYRINGES MARKET, BY REGION, 2016–2023 (USD BILLION) 71
TABLE 26 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016–2023 (USD BILLION) 72
TABLE 27 FILLABLE SYRINGES MARKET, BY REGION, 2016–2023 (USD BILLION) 72
TABLE 28 PREFILLED SYRINGES MARKET, BY REGION, 2016–2023 (USD BILLION) 73
TABLE 29 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2016–2023 (USD BILLION) 74
TABLE 30 REUSABLE SYRINGES MARKET, BY REGION, 2016–2023 (USD BILLION) 74
TABLE 31 DISPOSABLE SYRINGES MARKET, BY REGION, 2016–2023 (USD BILLION) 75
TABLE 32 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2016–2023 (USD BILLION) 76
TABLE 33 INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY REGION, 2016–2023 (USD BILLION) 76
TABLE 34 NEEDLE-FREE INJECTORS MARKET, BY REGION, 2016–2023 (USD BILLION) 77
TABLE 35 AUTOINJECTORS MARKET, BY REGION, 2016–2023 (USD BILLION) 78
TABLE 36 COMMERCIALLY AVAILABLE KEY PEN INJECTORS 78
TABLE 37 PEN INJECTORS MARKET, BY REGION, 2016–2023 (USD BILLION) 79
TABLE 38 WEARABLE INJECTORS MARKET, BY REGION, 2016–2023 (USD MILLION) 79
TABLE 39 OTHER INJECTOR DEVICES MARKET, BY REGION, 2016–2023 (USD BILLION) 80
TABLE 40 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY,
2016–2023 (USD BILLION) 81
TABLE 41 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD BILLION) 81
TABLE 42 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS,
BY DOSAGE FORM, 2016–2023 (USD BILLION) 82
TABLE 43 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS,
BY REGION, 2016–2023 (USD BILLION) 82
TABLE 44 TOPICAL SOLUTIONS MARKET, BY REGION, 2016–2023 (USD BILLION) 83
TABLE 45 TOPICAL SUSPENSIONS MARKET, BY REGION, 2016–2023 (USD BILLION) 84
TABLE 46 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD BILLION) 84
TABLE 47 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY REGION, 2016–2023 (USD BILLION) 85
TABLE 48 TOPICAL CREAMS MARKET, BY REGION, 2016–2023 (USD BILLION) 85
TABLE 49 TOPICAL GELS MARKET, BY REGION, 2016–2023 (USD MILLION) 86
TABLE 50 TOPICAL OINTMENTS MARKET, BY REGION, 2016–2023 (USD BILLION) 87
TABLE 51 TOPICAL PASTES MARKET, BY REGION, 2016–2023 (USD MILLION) 87
TABLE 52 TOPICAL LOTIONS MARKET, BY REGION, 2016–2023 (USD BILLION) 88
TABLE 53 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS,
BY DOSAGE FORM, 2016–2023 (USD MILLION) 88
TABLE 54 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS,
BY REGION, 2016–2023 (USD MILLION) 89
TABLE 55 TOPICAL SUPPOSITORIES MARKET, BY REGION, 2016–2023 (USD MILLION) 89
TABLE 56 TOPICAL POWDERS MARKET, BY REGION, 2016–2023 (USD BILLION) 90
TABLE 57 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2016–2023 (USD BILLION) 91
TABLE 58 TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY REGION, 2016–2023 (USD BILLION) 91
TABLE 59 TRANSDERMAL PATCHES MARKET, BY REGION, 2016–2023 (USD MILLION) 92
TABLE 60 TRANSDERMAL GELS MARKET, BY REGION, 2016–2023 (USD MILLION) 92
TABLE 61 OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY,
2016–2023 (USD BILLION) 94
TABLE 62 OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD BILLION) 94
TABLE 63 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS,
BY DOSAGE FORM, 2016–2023 (USD BILLION) 95
TABLE 64 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS,
BY REGION, 2016–2023 (USD BILLION) 95
TABLE 65 COMMERCIALLY AVAILABLE EYE DROPS 96
TABLE 66 EYE DROPS MARKET, BY REGION, 2016–2023 (USD BILLION) 96
TABLE 67 LIQUID SPRAYS MARKET, BY REGION, 2016–2023 (USD BILLION) 97
TABLE 68 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD MILLION) 97
TABLE 69 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY REGION, 2016–2023 (USD MILLION) 98
TABLE 70 OCULAR GELS MARKET, BY REGION, 2016–2023 (USD BILLION) 98
TABLE 71 EYE OINTMENTS MARKET, BY REGION, 2016–2023 (USD MILLION) 99
TABLE 72 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016–2023 (USD MILLION) 99
TABLE 73 OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES,
BY REGION, 2016–2023 (USD MILLION) 100
TABLE 74 DRUG-COATED CONTACT LENSES MARKET, BY REGION,
2016–2023 (USD MILLION) 100
TABLE 75 OCULAR INSERTS MARKET, BY REGION, 2016–2023 (USD BILLION) 101
TABLE 76 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY,
2016–2023 (USD BILLION) 102
TABLE 77 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD BILLION) 103
TABLE 78 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD BILLION) 103
TABLE 79 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR METERED-DOSE INHALERS, BY REGION, 2016–2023 (USD BILLION) 104
TABLE 80 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR DRY POWDER INHALERS, BY REGION, 2016–2023 (USD BILLION) 105
TABLE 81 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS,
BY TYPE, 2016–2023 (USD BILLION) 105
TABLE 82 PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS,
BY REGION, 2016–2023 (USD BILLION) 106
TABLE 83 JET NEBULIZERS MARKET, BY REGION, 2016–2023 (USD MILLION) 107
TABLE 84 ULTRASONIC NEBULIZERS MARKET, BY REGION, 2016–2023 (USD MILLION) 107
TABLE 85 SOFT MIST NEBULIZERS MARKET, BY REGION, 2016–2023 (USD MILLION) 108
TABLE 86 NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY,
2016–2023 (USD BILLION) 109
TABLE 87 NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM,
2016–2023 (USD BILLION) 109
TABLE 88 NASAL DROPS MARKET, BY REGION, 2016–2023 (USD BILLION) 110
TABLE 89 NASAL SPRAYS MARKET, BY REGION, 2016–2023 (USD BILLION) 111
TABLE 90 NASAL POWDERS MARKET, BY REGION, 2016–2023 (USD MILLION) 111
TABLE 91 NASAL GELS MARKET, BY REGION, 2016–2023 (USD MILLION) 112
TABLE 92 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY,
2016–2023 (USD BILLION) 113
TABLE 93 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD BILLION) 114
TABLE 94 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016–2023 (USD BILLION) 114
TABLE 95 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY REGION, 2016–2023 (USD BILLION) 115
TABLE 96 BUCCAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION,
2016–2023 (USD BILLION) 115
TABLE 97 SUBLINGUAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION,
2016–2023 (USD BILLION) 116
TABLE 98 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016–2023 (USD MILLION) 117
TABLE 99 TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY REGION, 2016–2023 (USD MILLION) 117
TABLE 100 RECTAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016–2023 (USD MILLION) 118
TABLE 101 VAGINAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016–2023 (USD MILLION) 119
TABLE 102 IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY,
2016–2023 (USD BILLION) 120
TABLE 103 IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD MILLION) 120
TABLE 104 ACTIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY REGION,
2016–2023 (USD MILLION) 121
TABLE 105 PASSIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016–2023 (USD BILLION) 122
TABLE 106 DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE,
2016–2023 (USD BILLION) 124
TABLE 107 DRUG DELIVERY TECHNOLOGY MARKET FOR HOSPITALS, BY REGION,
2016–2023 (USD BILLION) 125
TABLE 108 DRUG DELIVERY TECHNOLOGY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY REGION, 2016–2023 (USD BILLION) 126
TABLE 109 DRUG DELIVERY TECHNOLOGY MARKET FOR HOME CARE SETTINGS, BY REGION, 2016–2023 (USD BILLION) 126
TABLE 110 DRUG DELIVERY TECHNOLOGY MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2016–2023 (USD BILLION) 127
TABLE 111 DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FACILITIES OF USE,
BY REGION, 2016–2023 (USD BILLION) 128
TABLE 112 DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION,
2016–2023 (USD BILLION) 130
TABLE 113 DRUG DELIVERY TECHNOLOGY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2016–2023 (USD BILLION) 131
TABLE 114 DRUG DELIVERY TECHNOLOGY MARKET FOR CANCER, BY REGION,
2016–2023 (USD BILLION) 132
TABLE 115 DRUG DELIVERY TECHNOLOGY MARKET FOR CARDIOVASCULAR DISEASES,
BY REGION, 2016–2023 (USD BILLION) 133
TABLE 116 DRUG DELIVERY TECHNOLOGY MARKET FOR DIABETES, BY REGION,
2016–2023 (USD BILLION) 134
TABLE 117 DRUG DELIVERY TECHNOLOGY MARKET FOR RESPIRATORY DISEASES, BY REGION, 2016–2023 (USD BILLION) 135
TABLE 118 DRUG DELIVERY TECHNOLOGY MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2016–2023 (USD BILLION) 136
TABLE 119 DRUG DELIVERY TECHNOLOGY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2016–2023 (USD BILLION) 137
TABLE 120 DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER APPLICATIONS, BY REGION, 2016–2023 (USD BILLION) 138
TABLE 121 DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2016–2023 (USD BILLION) 140
TABLE 122 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY,
2016–2023 (USD BILLION) 142
TABLE 123 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD BILLION) 142
TABLE 124 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD BILLION) 142
TABLE 125 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2016–2023 (USD BILLION) 143
TABLE 126 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2016–2023 (USD BILLION) 143
TABLE 127 NORTH AMERICA: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2016–2023 (USD BILLION) 143
TABLE 128 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2023 (USD BILLION) 144
TABLE 129 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016–2023 (USD BILLION) 144
TABLE 130 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016–2023 (USD BILLION) 144
TABLE 131 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2016–2023 (USD BILLION) 145
TABLE 132 NORTH AMERICA: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2016–2023 (USD BILLION) 145
TABLE 133 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2023 (USD BILLION) 145
TABLE 134 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD BILLION) 146
TABLE 135 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD MILLION) 146
TABLE 136 NORTH AMERICA: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016–2023 (USD MILLION) 146
TABLE 137 NORTH AMERICA: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016–2023 (USD MILLION) 147
TABLE 138 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2023 (USD BILLION) 147
TABLE 139 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD BILLION) 147
TABLE 140 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD MILLION) 148
TABLE 141 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD MILLION) 148
TABLE 142 NORTH AMERICA: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2016–2023 (USD MILLION) 148
TABLE 143 NORTH AMERICA: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET,
BY TYPE, 2016–2023 (USD MILLION) 149
TABLE 144 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET,
BY TYPE, 2016–2023 (USD MILLION) 149
TABLE 145 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016–2023 (USD BILLION) 149
TABLE 146 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016–2023 (USD MILLION) 150
TABLE 147 NORTH AMERICA: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET,
BY TYPE, 2016–2023 (USD BILLION) 150
TABLE 148 NORTH AMERICA: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2016–2023 (USD MILLION) 150
TABLE 149 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION, 2016–2023 (USD BILLION) 151
TABLE 150 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE, 2016–2023 (USD BILLION) 151
TABLE 151 US: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD BILLION) 152
TABLE 152 US: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE,
2016–2023 (USD BILLION) 153
TABLE 153 CANADA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD BILLION) 154
TABLE 154 CANADA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE,
2016–2023 (USD BILLION) 154
TABLE 155 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY,
2016–2023 (USD BILLION) 156
TABLE 156 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD BILLION) 156
TABLE 157 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD BILLION) 157
TABLE 158 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS,
BY DOSAGE FORM, 2016–2023 (USD BILLION) 157
TABLE 159 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS,
BY DOSAGE FORM, 2016–2023 (USD BILLION) 157
TABLE 160 EUROPE: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS, BY DOSAGE FORM, 2016–2023 (USD BILLION) 158
TABLE 161 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD BILLION) 158
TABLE 162 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016–2023 (USD BILLION) 158
TABLE 163 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016–2023 (USD BILLION) 159
TABLE 164 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2016–2023 (USD BILLION) 159
TABLE 165 EUROPE: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2016–2023 (USD BILLION) 159
TABLE 166 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD BILLION) 160
TABLE 167 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD BILLION) 160
TABLE 168 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD MILLION) 160
TABLE 169 EUROPE: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016–2023 (USD MILLION) 161
TABLE 170 EUROPE: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016–2023 (USD MILLION) 161
TABLE 171 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD BILLION) 161
TABLE 172 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD BILLION) 162
TABLE 173 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD BILLION) 162
TABLE 174 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD MILLION) 162
TABLE 175 EUROPE: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2016–2023 (USD MILLION) 163
TABLE 176 EUROPE: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD MILLION) 163
TABLE 177 EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2023 (USD MILLION) 163
TABLE 178 EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016–2023 (USD BILLION) 164
TABLE 179 EUROPE: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016–2023 (USD MILLION) 164
TABLE 180 EUROPE: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD BILLION) 164
TABLE 181 EUROPE: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS, BY TYPE, 2016–2023 (USD MILLION) 165
TABLE 182 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION,
2016–2023 (USD BILLION) 165
TABLE 183 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE,
2016–2023 (USD BILLION) 166
TABLE 184 GERMANY: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD BILLION) 167
TABLE 185 GERMANY: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE,
2016–2023 (USD BILLION) 167
TABLE 186 FRANCE: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD BILLION) 168
TABLE 187 FRANCE: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE,
2016–2023 (USD BILLION) 169
TABLE 188 UK: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD BILLION) 170
TABLE 189 UK: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE,
2016–2023 (USD BILLION) 170
TABLE 190 ROE: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD BILLION) 171
TABLE 191 ROE: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE,
2016–2023 (USD BILLION) 172
TABLE 192 APAC: DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY,
2016-2023 (USD BILLION) 174
TABLE 193 APAC: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD BILLION) 174
TABLE 194 APAC: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2016-2023 (USD BILLION) 175
TABLE 195 APAC: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS,
BY DOSAGE FORM, 2016-2023 (USD BILLION) 175
TABLE 196 APAC: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS,
BY DOSAGE FORM, 2016-2023 (USD BILLION) 175
TABLE 197 APAC: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS,
BY DOSAGE FORM, 2016-2023 (USD BILLION) 176
TABLE 198 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016-2023 (USD BILLION) 176
TABLE 199 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016–2023 (USD BILLION) 176
TABLE 200 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016–2023 (USD BILLION) 177
TABLE 201 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2016–2023 (USD BILLION) 177
TABLE 202 APAC: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2016–2023 (USD BILLION) 177
TABLE 203 APAC: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD BILLION) 178
TABLE 204 APAC: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD BILLION) 178
TABLE 205 APAC: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD MILLION) 178
TABLE 206 APAC: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES,
BY TYPE, 2016–2023 (USD MILLION) 179
TABLE 207 APAC: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM,
2016–2023 (USD MILLION) 179
TABLE 208 APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD BILLION) 179
TABLE 209 APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD BILLION) 180
TABLE 210 APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD BILLION) 180
TABLE 211 APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD MILLION) 180
TABLE 212 APAC: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, 2016–2023 (USD MILLION) 181
TABLE 213 APAC: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD MILLION) 181
TABLE 214 APAC: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD MILLION) 181
TABLE 215 APAC: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016–2023 (USD BILLION) 182
TABLE 216 APAC: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016–2023 (USD MILLION) 182
TABLE 217 APAC: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD BILLION) 182
TABLE 218 APAC: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS,
BY TYPE, 2016–2023 (USD MILLION) 183
TABLE 219 APAC: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION,
2016–2023 (USD BILLION) 183
TABLE 220 APAC: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE,
2016–2023 (USD BILLION) 184
TABLE 221 JAPAN: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD BILLION) 185
TABLE 222 JAPAN: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE,
2016–2023 (USD BILLION) 185
TABLE 223 CHINA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD BILLION) 186
TABLE 224 CHINA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE,
2016–2023 (USD BILLION) 187
TABLE 225 INDIA: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD BILLION) 188
TABLE 226 INDIA: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE,
2016–2023 (USD BILLION) 188
TABLE 227 ROAPAC: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD MILLION) 189
TABLE 228 ROA: DRUG DELIVERY TECHNOLOGY MARKET, BY END USER,
2016–2023 (USD BILLION) 190
TABLE 229 ROW: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD BILLION) 192
TABLE 230 ROW: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM,
2016-2023 (USD BILLION) 192
TABLE 231 ROW: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS,
BY DOSAGE FORM, 2016-2023 (USD BILLION) 193
TABLE 232 ROW: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID DRUGS,
BY DOSAGE FORM, 2016-2023 (USD BILLION) 193
TABLE 233 ROW: ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID DRUGS,
BY DOSAGE FORM, 2016-2023 (USD MILLION) 193
TABLE 234 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016-2023 (USD MILLION) 194
TABLE 235 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2016–2023 (USD BILLION) 194
TABLE 236 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2016–2023 (USD BILLION) 194
TABLE 237 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR CONVENTIONAL DEVICES, 2016–2023 (USD BILLION) 195
TABLE 238 ROW: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET FOR SELF-INJECTION DEVICES MARKET, BY TYPE, 2016–2023 (USD MILLION) 195
TABLE 239 ROW: OCULAR DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD MILLION) 195
TABLE 240 ROW: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD BILLION) 196
TABLE 241 ROW: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD MILLION) 196
TABLE 242 ROW: OCULAR DRUG DELIVERY TECHNOLOGY MARKET FOR OCULAR DEVICES, BY TYPE, 2016–2023 (USD MILLION) 196
TABLE 243 ROW: NASAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM,
2016–2023 (USD MILLION) 197
TABLE 244 ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD MILLION) 197
TABLE 245 ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD MILLION) 197
TABLE 246 ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SEMI-SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD MILLION) 198
TABLE 247 ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2016–2023 (USD MILLION) 198
TABLE 248 ROW: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2016–2023 (USD MILLION) 198
TABLE 249 ROW: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2023 (USD MILLION) 199
TABLE 250 ROW: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2016–2023 (USD MILLION) 199
TABLE 251 ROW: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2016–2023 (USD MILLION) 199
TABLE 252 ROW: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2016–2023 (USD MILLION) 200
TABLE 253 ROW: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE,
2016–2023 (USD MILLION) 200
TABLE 254 ROW: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET FOR NEBULIZERS,
BY TYPE, 2016–2023 (USD MILLION) 200
TABLE 255 ROW: DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION,
2016–2023 (USD BILLION) 201
TABLE 256 ROW: DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE,
2016–2023 (USD BILLION) 201
TABLE 257 DRUG DELIVERY TECHNOLOGY MARKET PLAYER RANKING, 2017 203
TABLE 258 PRODUCT LAUNCHES AND APPROVALS, 2016–2018 204
TABLE 259 COLLABORATIONS, AGREEMENTS, AND JOINT VENTURES, 2016–2018 204
TABLE 260 ACQUISITIONS, 2015–2018 205
TABLE 261 EXPANSIONS, 2015–2018 205


LIST OF FIGURES

FIGURE 1 DRUG DELIVERY TECHNOLOGY MARKET SEGMENTATION 29
FIGURE 2 DRUG DELIVERY TECHNOLOGY MARKET: RESEARCH METHODOLOGY 31
FIGURE 3 RESEARCH DESIGN 32
FIGURE 4 FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 34
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 37
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 37
FIGURE 7 DATA TRIANGULATION METHODOLOGY 38
FIGURE 8 DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION,
2018 VS. 2023 (USD BILLION) 40
FIGURE 9 ORAL DRUG DELIVERY TECHNOLOGY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2018 VS. 2023 (USD BILLION) 41
FIGURE 10 DRUG DELIVERY TECHNOLOGY MARKET, BY FACILITY OF USE,
2018 VS. 2023 (USD BILLION) 41
FIGURE 11 DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION,
2018 VS. 2023 (USD BILLION) 42
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE DRUG DELIVERY TECHNOLOGY MARKET 43
FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASES IS DRIVING THE GROWTH OF THE DRUG DELIVERY TECHNOLOGY MARKET 44
FIGURE 14 TOPICAL DRUG DELIVERY SEGMENT TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 45
FIGURE 15 HOSPITALS ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2018 45
FIGURE 16 INFECTIOUS DISEASES APPLICATION SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2018 46
FIGURE 17 CHINA IS EXPECTED TO GROW AT THE HIGHEST RATE DURING
THE FORECAST PERIOD 47
FIGURE 18 DRUG DELIVERY TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48
FIGURE 19 TOPICAL DRUG DELIVERY TO WITNESS HIGHEST GROWTH DURING
THE FORECAST PERIOD 54
FIGURE 20 HOME CARE SETTINGS TO WITNESS THE HIGHEST GROWTH IN THE DRUG DELIVERY TECHNOLOGY MARKET FROM 2018 TO 2023 124
FIGURE 21 INFECTIOUS DISEASES SEGMENT WILL CONTINUE TO DOMINATE THE DRUG DELIVERY TECHNOLOGY MARKET DURING THE FORECAST PERIOD 130
FIGURE 22 NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT 141
FIGURE 23 EUROPE: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT 155
FIGURE 24 ASIA PACIFIC: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT 173
FIGURE 25 ROW: DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT 191
FIGURE 26 KEY DEVELOPMENTS IN THE DRUG DELIVERY TECHNOLOGY MARKET FROM
2016 TO 2019 202
FIGURE 27 MNM DIVE-VENDOR COMPARISON MATRIX: DRUG DELIVERY TECHNOLOGY MARKET 207
FIGURE 28 MNM DIVE-VENDOR COMPARISON MATRIX FOR START-UPS: DRUG DELIVERY TECHNOLOGY MARKET 209
FIGURE 29 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2017) 210
FIGURE 30 NOVARTIS AG: COMPANY SNAPSHOT (2017) 221
FIGURE 31 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2017) 231
FIGURE 32 PFIZER, INC.: COMPANY SNAPSHOT (2017) 236
FIGURE 33 BAYER AG: COMPANY SNAPSHOT (2017) 249
FIGURE 34 ANTARES PHARMA, INC.: COMPANY SNAPSHOT (2017) 254
FIGURE 35 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2017) 256
FIGURE 36 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2017) 260
FIGURE 37 3M: COMPANY SNAPSHOT (2017) 267
FIGURE 38 MERCK & CO., INC.: COMPANY SNAPSHOT (2017) 269
FIGURE 39 SANOFI: COMPANY SNAPSHOT (2017) 276


★調査レポート[薬剤送達システムの世界市場予測(~2023年)] ( Pharmaceutical Drug Delivery Market by Route (Oral (Tablet), Pulmonary (Nebulizer), Injectable, Ocular (Liquid), Topical (Solid), Implantable (Active), Transmucosal), Application (Cancer, Diabetes), Patient Care Setting (Hospital) - Global Forecast to 2023 / MD 3871) 販売に関する免責事項
[薬剤送達システムの世界市場予測(~2023年)] ( Pharmaceutical Drug Delivery Market by Route (Oral (Tablet), Pulmonary (Nebulizer), Injectable, Ocular (Liquid), Topical (Solid), Implantable (Active), Transmucosal), Application (Cancer, Diabetes), Patient Care Setting (Hospital) - Global Forecast to 2023 / MD 3871) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆